RT Journal Article
SR Electronic
T1 Mortality and lost to follow-up among Tuberculosis patients on treatment in Meru County, Kenya: a retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.15.24315529
DO 10.1101/2024.10.15.24315529
A1 Ngari, Moses M.
A1 Mberia, Jane K.
A1 Kanana, Eunice
A1 Sanga, Deche
A1 Ngari, Martin K.
A1 Nyagah, David N.
A1 Abdullahi, Osman A.
YR 2024
UL http://medrxiv.org/content/early/2024/10/16/2024.10.15.24315529.abstract
AB Tuberculosis (TB) remains a leading cause of death globally. Patients who get lost-to-follow-up (LTFU) during TB treatment have high risk of relapse, mortality, treatment failure and developing Multidrug resistant TB. Empirical data to monitor long-term TB treatment outcomes in low-and-middle income countries (LMICs) are sparse. We determined proportion of TB patients who die or are LTFU during six months of treatment and identified factors independently associated with mortality or LTFU. A retrospective cohort using data from routine Meru County TB surveillance system. We included 38020 records of TB patients aged ≥15 years on treatment 2012 to 2022. TB treatment outcomes of interest were LTFU or death within six months of treatment. Survival analyses accounting for competing events were performed. Among the 38020 patients included, 27608 (73%) were male and the median (IQR) age was 32 [25‒42] years. 26599 (70%) had bacteriologically confirmed TB while 11421 (30%) were clinically diagnosed. During 16531 person-years of follow-up, 2385 (6.3%, 95%CI 6.0‒6.5) and 1942 (5.1%, 95%CI 4.9‒5.3) patients were LTFU and died respectively. In the multivariable model, patients on re-treatment after LTFU or after failure and those previously treated compared to new TB patients were positively associated with LTFU. Patients coinfected with HIV and those with unknown HIV status were positively associated with LTFU. In contrast, females, clinically diagnosed, extra-pulmonary TB and older patients were negatively associated with LTFU. Patients HIV infected on ARVs, not on ARVs and unknown HIV status versus not infected were positively associated with mortality. Other comorbidities (not HIV), clinically diagnosed, undernourished and older patients were positively associated with mortality. More than 10% of TB patients either die or are LTFU before completing treatment. TB patients on re-treatment, HIV infected, clinically diagnosed, undernourished and the elderly needs more targeted interventions to improve survival and successfully treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was not funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was granted by the Pwani University Ethics Review Committee (ISERC/PU-STAFF/003/2024) and permit to conduct the study granted by Department of Health, Meru County (MRU/GEN/GEN/C.50). Study participants and caregivers for children less than eighteen years old provided written informed consent for their data to be used.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes